Role of CD-10 as a stromal marker in prognosis of Breast cancer and correlation with axillary lymph nodes positivity.
Keywords:
Breast carcinoma, CD-10, IDC(Infiltrating ductal carcinoma), axillary lymph nodes, stromal cells.
Abstract
Background:Breast carcinoma is the most common non-skin malignancy in women. In India, cancer of the breast is the most common cancer among women in many regions and has over taken cervix cancer, which was the most frequent cancer a decade ago .CD10 is a 90-110kd cell surface zinc-dependent metalloproteinase. Since CD10 is structurally similar to matrix metalloproteinase and stromelysin, it might facilitate cancer cell invasion and/or metastasis. The aim of this study is to highlight the role of CD 10,a stromal ,marker present in case of infiltrating ductal carcinoma of breast, in prognostication of IDC and also shows incidence of CD 10 positivity with lymph node metastasis..Methods: By using DAKO kit, immunohistochemistry for CD 10 as a marker was performed on the slides prepared from these blocks. Result: We present a original study of 50 histologically proven cases of breast carcinoma, comprising of 47 (94%) as IDC, 02(4%) as Lobular carcinoma and 01 (2%) as papillary carcinoma. Out of 40 CD 10 positive cases of IDC,38 (88%) were showing lymph node metastasis.Conclusion:It has been postulated that CD10 induced by cancer cells through soluble factor, similar to other member of metalloproteinase family.CD 10 positive stromal cells also detected in metastatic lymph node of infiltrating ductal carcinoma and significantly exhibit more nodal involvement.DOI:10.21276/APALM.1493References
1. ICMR [Internet]: Two- year report of the population based cancer registries,1999-2000, National cancer registry program me. Available from: http://www.icmr.nic.in/ncrp/1999-00/PBCR%20Report%20 1999_00.pdf [Last accessed on 2013 Nov 15].
2. Albrecht M, Gillen S, Wilhelm B, et al. Expression,localization and activity of neutral endopeptidase in cultured cells of benign prostatic hyperplasia and prostate cancer. J Urol 2002;168:336–342.
3. Iwaya K, Ogawa H, Izumi M, et al. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome. Virchows Arch 2002;440:589–593.
4. Kesse-Adu R, Shousha S. Myoepithelial markers are expressed in at least 29% of oestrogen receptor negative invasive breast carcinoma. Mod Pathol 2004;17:646–652.
5. Tokuhara T, Adachi M, Hashida H, et al. Neutral endopeptidase/CD10 and aminopeptidase N/CD13 gene expression as a prognostic factor in non-small cell lung cancer. Jpn J Thorac Cardiovasc Surg 2001;49:489–496.
6. Kristiansen G, Schluns K, Yongwei Y, et al. CD10 expression in non-small cell lung cancer. Anal Cell Pathol 2002;24:41–46.
7. Popnikolov NK, Ayala AG, Graves K, et al. Benign myoepithelial tumors of the breast have immunophenotypic characteristics similar to metaplastic matrixproducing and spindle cell carcinomas. Am J Clin Pathol 2003;120:161–167.
8. Huang WB, Zhou XJ, Chen JY, et al. CD10-positive stromal cells in gastric carcinoma: correlation with invasion and metastasis. Jpn J Clin Oncol 2005;35: 245–250.
9. Tse GM, Tsang AK, Putti TC, et al. Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours. J Clin Pathol 2005;58:185–189.
10. Maguer-Satta V, Besançon R, Bachelard-Cascales E. Concise review: neutral endopeptidase (CD10): a multifaceted environment actor in stem cells, physiological mechanisms, and cancer. Stem Cells. 2011;29(3):389–96.
11. Moritani S, Kushima R, Sugihara H, Bamba M, Kobayashi TK, Hattori T. Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections. Mod Pathol. 2002;15(4):397–405
12. Huang WB, Zhou XJ, Chen JY, Zhang LH, Meng K, Ma HH, et al. CD10-positive stromal cells in gastric carcinoma: correlation with invasion and metastasis. Jpn Clin Oncol. 2005;35(5):245–50.
13. Tokuhara T, Adachi M, Hashida H, Ishida H, Taki T, Higashiyama M, et al. Neutral endopeptidase/CD10 and aminopeptidase N/CD13 gene expression as a prognostic factor in non-small cell lung cancer. Jpn J Thorac Cardiovasc Surg. 2001;49(8):489–96
14. Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod Pathol. 2007;20(1):84–9
15. Voutsadakis IA, Vlachostergios PJ, Daliani DD, Karasavvidou F, Kakkas G, Moutzouris G, et al. CD10 Is Inversely Associated with Nuclear Factor-Kappa B and Predicts Biochemical Recurrence after Radical Prostatectomy. Urol Int. 2012;88(2):158–64
16. Ogawa H, Iwaya K, Izumi M, Kuroda M, Serizawa H, Koyanagi Y, et al. Expression of CD10 by stromal cells during colorectal tumor development. Hum Pathol. 2002;33(8):806–11
17. Hasebe T, Tsuda H, Hirohashi S, Shimosato Y, Iwai M, Imoto S, et al (1996) Fibrotic focus in invasive ductal carcinoma: an indicator of high tumor aggressiveness. Jpn J Cancer Res 87:385–394,1.
18. Keiichi Iwaya Hitoshi Ogawa Miki Izumi Masahiko Kuroda Kiyoshi Mukai Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome. 2002 440:589–593 DOI 10.1007/s00428-002-0639-4
19. Basset P, Wolf C, Rouyer N, Bellocq JP, Rio MC, Chambon P (1994) Stromelysin-3 in stromal tissue as a control factor in breast cancer behavior. Cancer 74:1045–1049.
20. Talvensaari-Mattila A, Paakko P, Hoyhtya M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T (1998) Matrix metalloproteinase- immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 83:1153-1162.
21. De Wever and M. Mareel, “Role of tissue stroma in cancer cell invasion,” Journal of Pathology, vol. 200, no. 4, pp. 429–447, 2003.
22. Sayantan H. Jana, Bharti M. Jha, Chandni Patel, Dipan Jana, Anshul Agarwal CD10-A new prognostic stromal marker in breast carcinoma, its utility, limitations and role in breast cancer pathogenesis. January 26, 2015, IP: 122.175.144.151
23. Vandana Puri, Manjula Jain, and Shaji Thomas 2011Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67. International Journal of Breast cancer vol. 2011, article ID 437957, P 4.
24. Nikita A Makretsov, Malcolm Hayes, Beverley A Carter, Shahriar Dabiri1, C Blake Gilks and David G Huntsman,stromal CD10 expression in invasive breast carcinoma correlate with poor prognosis,estrogen receptor negativity and high grade,modern pathology (2007)20, 84-89.
2. Albrecht M, Gillen S, Wilhelm B, et al. Expression,localization and activity of neutral endopeptidase in cultured cells of benign prostatic hyperplasia and prostate cancer. J Urol 2002;168:336–342.
3. Iwaya K, Ogawa H, Izumi M, et al. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome. Virchows Arch 2002;440:589–593.
4. Kesse-Adu R, Shousha S. Myoepithelial markers are expressed in at least 29% of oestrogen receptor negative invasive breast carcinoma. Mod Pathol 2004;17:646–652.
5. Tokuhara T, Adachi M, Hashida H, et al. Neutral endopeptidase/CD10 and aminopeptidase N/CD13 gene expression as a prognostic factor in non-small cell lung cancer. Jpn J Thorac Cardiovasc Surg 2001;49:489–496.
6. Kristiansen G, Schluns K, Yongwei Y, et al. CD10 expression in non-small cell lung cancer. Anal Cell Pathol 2002;24:41–46.
7. Popnikolov NK, Ayala AG, Graves K, et al. Benign myoepithelial tumors of the breast have immunophenotypic characteristics similar to metaplastic matrixproducing and spindle cell carcinomas. Am J Clin Pathol 2003;120:161–167.
8. Huang WB, Zhou XJ, Chen JY, et al. CD10-positive stromal cells in gastric carcinoma: correlation with invasion and metastasis. Jpn J Clin Oncol 2005;35: 245–250.
9. Tse GM, Tsang AK, Putti TC, et al. Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours. J Clin Pathol 2005;58:185–189.
10. Maguer-Satta V, Besançon R, Bachelard-Cascales E. Concise review: neutral endopeptidase (CD10): a multifaceted environment actor in stem cells, physiological mechanisms, and cancer. Stem Cells. 2011;29(3):389–96.
11. Moritani S, Kushima R, Sugihara H, Bamba M, Kobayashi TK, Hattori T. Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections. Mod Pathol. 2002;15(4):397–405
12. Huang WB, Zhou XJ, Chen JY, Zhang LH, Meng K, Ma HH, et al. CD10-positive stromal cells in gastric carcinoma: correlation with invasion and metastasis. Jpn Clin Oncol. 2005;35(5):245–50.
13. Tokuhara T, Adachi M, Hashida H, Ishida H, Taki T, Higashiyama M, et al. Neutral endopeptidase/CD10 and aminopeptidase N/CD13 gene expression as a prognostic factor in non-small cell lung cancer. Jpn J Thorac Cardiovasc Surg. 2001;49(8):489–96
14. Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod Pathol. 2007;20(1):84–9
15. Voutsadakis IA, Vlachostergios PJ, Daliani DD, Karasavvidou F, Kakkas G, Moutzouris G, et al. CD10 Is Inversely Associated with Nuclear Factor-Kappa B and Predicts Biochemical Recurrence after Radical Prostatectomy. Urol Int. 2012;88(2):158–64
16. Ogawa H, Iwaya K, Izumi M, Kuroda M, Serizawa H, Koyanagi Y, et al. Expression of CD10 by stromal cells during colorectal tumor development. Hum Pathol. 2002;33(8):806–11
17. Hasebe T, Tsuda H, Hirohashi S, Shimosato Y, Iwai M, Imoto S, et al (1996) Fibrotic focus in invasive ductal carcinoma: an indicator of high tumor aggressiveness. Jpn J Cancer Res 87:385–394,1.
18. Keiichi Iwaya Hitoshi Ogawa Miki Izumi Masahiko Kuroda Kiyoshi Mukai Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome. 2002 440:589–593 DOI 10.1007/s00428-002-0639-4
19. Basset P, Wolf C, Rouyer N, Bellocq JP, Rio MC, Chambon P (1994) Stromelysin-3 in stromal tissue as a control factor in breast cancer behavior. Cancer 74:1045–1049.
20. Talvensaari-Mattila A, Paakko P, Hoyhtya M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T (1998) Matrix metalloproteinase- immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 83:1153-1162.
21. De Wever and M. Mareel, “Role of tissue stroma in cancer cell invasion,” Journal of Pathology, vol. 200, no. 4, pp. 429–447, 2003.
22. Sayantan H. Jana, Bharti M. Jha, Chandni Patel, Dipan Jana, Anshul Agarwal CD10-A new prognostic stromal marker in breast carcinoma, its utility, limitations and role in breast cancer pathogenesis. January 26, 2015, IP: 122.175.144.151
23. Vandana Puri, Manjula Jain, and Shaji Thomas 2011Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67. International Journal of Breast cancer vol. 2011, article ID 437957, P 4.
24. Nikita A Makretsov, Malcolm Hayes, Beverley A Carter, Shahriar Dabiri1, C Blake Gilks and David G Huntsman,stromal CD10 expression in invasive breast carcinoma correlate with poor prognosis,estrogen receptor negativity and high grade,modern pathology (2007)20, 84-89.
Published
2018-03-01
Issue
Section
Original Article
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
